Toshihide Nishimura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9161893/publications.pdf

Version: 2024-02-01

933447 794594 20 383 10 19 citations g-index h-index papers 22 22 22 617 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Proteomic analysis of laser-microdissected paraffin-embedded tissues: (1) Stage-related protein candidates upon non-metastatic lung adenocarcinoma. Journal of Proteomics, 2010, 73, 1089-1099.	2.4	80
2	Proteomic analysis of laser-microdissected paraffin-embedded tissues: (2) MRM assay for stage-related proteins upon non-metastatic lung adenocarcinoma. Journal of Proteomics, 2010, 73, 1100-1110.	2.4	64
3	Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma. Expert Review of Proteomics, 2017, 14, 373-386.	3.0	38
4	Differential Proteomic Analysis between Small Cell Lung Carcinoma (SCLC) and Pulmonary Carcinoid Tumors Reveals Molecular Signatures for Malignancy in Lung Cancer. Proteomics - Clinical Applications, 2018, 12, e1800015.	1.6	35
5	Current status of clinical proteogenomics in lung cancer. Expert Review of Proteomics, 2019, 16, 761-772.	3.0	27
6	Identification of key modules and hub genes for small-cell lung carcinoma and large-cell neuroendocrine lung carcinoma by weighted gene co-expression network analysis of clinical tissue-proteomes. PLoS ONE, 2019, 14, e0217105.	2.5	24
7	A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues. PLoS ONE, 2015, 10, e0123661.	2.5	19
8	A proteomic profile of synoviocyte lesions microdissected from formalin-fixed paraffin-embedded synovial tissues of rheumatoid arthritis. Clinical Proteomics, 2015, 12, 20.	2.1	16
9	A selected reaction monitoring mass spectrometric assessment of biomarker candidates diagnosing large-cell neuroendocrine lung carcinoma by the scaling method using endogenous references. PLoS ONE, 2017, 12, e0176219.	2.5	12
10	Disease proteomics toward bedside reality. Journal of Gastroenterology, 2005, 40, 7-13.	5.1	11
11	Mass spectrometry-based proteomic analysis of formalin-fixed paraffin-embedded extrahepatic cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 683-691.	2.6	11
12	Developments of mass spectrometry-based technologies for effective drug development linked with clinical proteomes. Drug Metabolism and Pharmacokinetics, 2016, 31, 3-11.	2.2	9
13	Disease-related cellular protein networks differentially affected under different EGFR mutations in lung adenocarcinoma. Scientific Reports, 2020, 10, 10881.	3.3	9
14	Mutant Proteomics of Lung Adenocarcinomas Harboring Different EGFR Mutations. Frontiers in Oncology, 2020, 10, 1494.	2.8	7
15	Clinical initiatives linking Japanese and Swedish healthcare resources on cancer studies utilizing Biobank Repositories. Clinical and Translational Medicine, 2014, 3, 61.	4.0	6
16	Protein co-expression network-based profiles revealed from laser-microdissected cancerous cells of lung squamous-cell carcinomas. Scientific Reports, 2021, 11, 20209.	3.3	5
17	A proteogenomic profile of early lung adenocarcinomas by protein co-expression network and genomic alteration analysis. Scientific Reports, 2020, 10, 13604.	3.3	4
18	Protein co-expression networks identified from HOT lesions of ER+HER2–Ki-67high luminal breast carcinomas. Scientific Reports, 2021, 11, 1705.	3.3	4

#	Article	lF	CITATIONS
19	Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care. International Journal of Proteomics, 2012, 2012, 1-10.	2.0	2
20	Indigenome and Indigenomics : Targeted Quantitative Analysis of Native Biomolecules on Their Expression and Variety of Indigenous Forms â€" Represented by Proteins â€". Bunseki Kagaku, 2012, 61, 445-457.	0.2	0